Cellular signaling underlying atrial tachycardia remodeling of L-type calcium current

Circ Res. 2008 Oct 10;103(8):845-54. doi: 10.1161/CIRCRESAHA.108.175463. Epub 2008 Aug 21.

Abstract

Atrial tachycardia (AT) downregulates L-type Ca(2+) current (I(CaL)) and causes atrial fibrillation-promoting electric remodeling. This study assessed potential underlying signal transduction. Cultured adult canine atrial cardiomyocytes were paced at 0, 1, or 3 Hz (P0, P1, P3) for up to 24 hours. Cellular tachypacing (P3) mimicked effects of in vivo AT: decreased I(CaL) and transient outward current (I(to)), unchanged I(CaT), I(Kr), and I(Ks), and reduced action potential duration (APD). I(CaL) was unchanged in P3 at 2 and 8 hours but decreased by 55+/-6% at 24 hours. Tachypacing caused Ca(2+)(i) accumulation in P3 cells at 2 to 8 hours, but, by 24 hours, Ca(2+)i returned to baseline. Ca(v)1.2 mRNA expression was not altered at 2 hours but decreased significantly at 8 and 24 hours (32+/-4% and 48+/-4%, respectively) and protein expression was decreased (47+/-8%) at 24 hours only. Suppressing Ca(2+)(i) increases during tachypacing with the I(CaL) blocker nimodipine or the Ca(2+) chelator BAPTA-AM prevented I(CaL) downregulation. Calcineurin activity increased in P3 at 2 and 8 hours, respectively, returning to baseline at 24 hours. Nuclear factor of activated T cells (NFAT) nuclear translocation was enhanced in P3 cells. Ca(2+)-dependent signaling was probed with inhibitors of Ca(2+)/calmodulin (W-7), calcineurin (FK-506), and NFAT (INCA6): each prevented I(CaL) downregulation. Significant APD reductions ( approximately 30%) at 24 hours in P3 cells were prevented by nimodipine, BAPTA-AM, W-7, or FK-506. Thus, rapid atrial cardiomyocyte activation causes Ca(2+) loading, which activates the Ca(2+)-dependent calmodulin-calcineurin-NFAT system to cause transcriptional downregulation of I(CaL), restoring Ca(2+)i to normal at the cost of APD reduction. These studies elucidate for the first time the molecular feedback mechanisms underlying arrhythmogenic AT remodeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Animals
  • Calcineurin / metabolism
  • Calcium Channel Blockers / pharmacology
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / genetics
  • Calcium Channels, L-Type / metabolism*
  • Calcium Signaling* / drug effects
  • Calmodulin / antagonists & inhibitors
  • Calmodulin / metabolism
  • Cardiac Pacing, Artificial
  • Cells, Cultured
  • Chelating Agents / pharmacology
  • Dogs
  • Egtazic Acid / analogs & derivatives
  • Egtazic Acid / pharmacology
  • Heart Atria / metabolism
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / metabolism*
  • NFATC Transcription Factors / metabolism
  • Nimodipine / pharmacology
  • Potassium / metabolism
  • RNA, Messenger / metabolism
  • Sulfonamides / pharmacology
  • Tachycardia, Supraventricular / metabolism*
  • Tacrolimus / pharmacology
  • Time Factors
  • Transcription, Genetic

Substances

  • Calcium Channel Blockers
  • Calcium Channels, L-Type
  • Calmodulin
  • Chelating Agents
  • L-type calcium channel alpha(1C)
  • NFATC Transcription Factors
  • RNA, Messenger
  • Sulfonamides
  • 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester
  • Egtazic Acid
  • Nimodipine
  • W 7
  • Calcineurin
  • Potassium
  • Tacrolimus